|Videos|March 17, 2023
Optimal Use Cases for Clascoterone Cream 1%
Dawn Eichenfield and Guy Webster discuss considerations relating to treating their patients with clascoterone cream 1%.
Advertisement
Episodes in this series
Advertisement
Related to this article
Treatment success reached 56.7% and total lesions fell 71.8% with up to 52 weeks of oral denifanstat, with no adverse event-related discontinuations.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Remibrutinib for Symptomatic Dermographism
2
Evaluating the Evidence for Emerging Oral Therapies in Psoriasis
3
EADV 2026: HS Assessment and Follow-Up for NPs and PAs
4
Omlyclo, First Interchangeable Xolair Biosimilar, Launches in the US
5